Table 1.

Clinicopathologic characteristics of sequenced colorectal carcinoma cases

RTK/MAP2K1 wild type (n = 229 of 694)aRTK Altered (n = 52: 26 TCGA+ 26 MSK-IMPACT)MAP2K1 Mutated (n = 10: 3 Sequenom, 3 MSK-IMPACT, 4 TCGA)
Age (mean, median)56, 5761, 6255, 57
Sex (M:F)125:10434:188:2
KRAS/NRAS/BRAF Mutation137 (60%)19 (37%) (P = 0.003)0 (P = 0.0002)
APC/CTNNB1 Mutation178 (78%)33 (63%)5 of 7 tested (71%)
TP53 Mutation134 (59%)39 (75%)6 of 7 tested (86%)
PIK3CA/PTEN alteration61 (27%)4 (8%) (P = 0.003)1 of 7 tested (14%)
Primary site (proximal, distal)84 (37%), 145 (63%)20 (38%), 32 (62%)3 (30%), 7 (70%)
MMR-Deficient/MSI-H12 (11%) of 114 tested1 (4%) of 25 tested0 of 6 tested
20q Gain28 (12%)8 (15%)0 of 7 tested
Mucinous differentiation5 (2%)4 (8%)0
Poor differentiation17 (7%)10 (19%)2 (20%)

NOTE: P values <0.01 were considered significant and are listed in bold.

  • aTCGA RTK/MAP2K1 wild-type cases were excluded from wild-type clinicopathologic analysis due to limited data.